Form 4: Halozyme Therapeutics Executive Trades Shares

Halozyme Therapeutics EVP David A. Ramsay reports transactions involving common stock, restricted stock units, and stock options.

Summary

• David A. Ramsay, EVP, President, Drug Delivery at Halozyme Therapeutics, Inc., reported several transactions on June 30, 2026, and July 1, 2026.
• On June 30, 2026, 10,000 shares of common stock were acquired at $0, and 5,408 shares were disposed of at $78.27, with the remaining 4,592 shares beneficially owned.
• The disposition of 5,408 shares was to cover tax withholding obligations.
• Restricted Stock Units (RSUs) totaling 10,000 vested and settled on June 30, 2026, with shares subject to a one-year holding period.
• An additional 16,232 RSUs were acquired on July 1, 2026, with a vesting schedule starting July 1, 2027.
• Options to purchase 39,823 shares of common stock were acquired on July 1, 2026, with an exercise price of $77.01, vesting starting July 1, 2027, and expiring July 1, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine executive stock transactions and compensation-related events rather than significant company performance indicators.

Positives

• Acquisition of 10,000 shares of common stock at no cost.
• Vesting and settlement of 10,000 Restricted Stock Units, indicating compensation realization.
• Acquisition of 16,232 additional Restricted Stock Units, suggesting future equity awards.
• Acquisition of options to purchase 39,823 shares of common stock, indicating potential for future gains.

Negatives

• Disposition of 5,408 shares of common stock to cover tax withholding obligations, representing a reduction in direct holdings.

Risks

• The shares received upon vesting of RSUs remain subject to a one-year holding period from the vesting date.
• Stock options have an exercise price of $77.01, meaning the stock price must exceed this for the options to be profitable.
• Vesting schedules for RSUs and stock options indicate a phased realization of equity value over time.

Future Outlook

The filing details the acquisition of stock options and restricted stock units with future vesting dates, indicating a long-term incentive structure for the executive. The stock options have an exercise price of $77.01 and expire in 2036, while RSUs have varying vesting schedules.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions. The details provided are typical for compensation packages involving stock options and restricted stock units, common in the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The transactions reflect executive compensation and potential future dilution if options are exercised. The disposition for tax withholding is a standard event.
• Employees: The structure of RSUs and options is a common incentive for key employees.
• Management: The filing details compensation-related equity awards for a key executive.

Next Steps

• Shares received from RSU vesting on June 30, 2026, are subject to a one-year holding period.
• Vesting of additional RSUs begins on July 1, 2027.
• Vesting of stock options begins on July 1, 2027.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Halozyme Therapeutics, HALO, Executive Compensation, Beneficial Ownership